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Cardiac sarcoidosis occurs in about 2 - 10% of sarcoidosis 
patients although prevalence of this disease varies signifi-cantly depending on the population studied and methodol-ogy used for detection [1-4]. The manifestations of cardiac sarcoidosis may include conduction abnormalities, heart failure, ventricular and atrial arrhythmias. In Japan, where cardiac sarcoidosis is more common than in western coun-tries, 50 - 70% of these patients died of cardiac events. In the majority of patients with cardiac sarcoidosis, the disease is limited to the heart or it is associated with a minimal ex-tra-cardiac involvement [5]. Early and accurate diagnosis of cardiac involvement is necessary in patients with sarcoid-osis to avoid sudden cardiac death and sever cardiovascular 
events. The diagnostic algorithm is very complex as histo-logical examination of myocardial tissue is hardly practi-cable [1-6]. The endomyocardial biopsy is falling out of fa-vour due to patchy myocardial involvement, considerable procedure-related risks and advancement in additional imaging modalities [6]. Therefore, diagnosis of cardiac sarcoidosis usually depends on identifying sarcoid gran-ulomas in other tissues with evidence of disease. An indi-rect diagnosis is based on histological evidence of extra-cardiac sarcoidosis in a patient with unexplained reduced left ventricular ejection fraction (< 40%), cardiac disease responsive to steroids or immunosuppressant, evidence of granulomatous sarcoidosis alterations on cardiac positron emission tomography (PET) or cardiovascular magnetic resonance or gallium uptake study [6,7]. 18F-FDG PET in particular seems to be very useful in evaluating active car-
diac sarcoid lesions and its specificity as diagnostic tool is very high [8]. No serological biomarker with adequate 
sensitivity and sensibility has been identified to improve the diagnosis of cardiac sarcoidosis and in particularly in patients with isolated cardiac involvement and no possi-bility to perform an extra-cardiac biopsy there is a need 
of a specific serological indicator [9]. Several biomarkers, such as cytokines, chemokines and macrophage- or lym-phocyte derived mediators including angiotensin convert-ing enzyme (ACE) and interleukin 2 receptor (IL2r) have 
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02been studied in systemic sarcoidosis (including sIL-2R, se-rum amyloid A, CRP, and angiotensin-converting enzyme) but few data is available about their expression in cardiac sarcoidosis, as well as in neurosarcoidosis, both manifes-
tations associated with significant morbidity and mortality [10-13]. However, no data is available about neopterin, chiti-nases and sIL2R in cardiac involvement while few papers re-port ACE and lysozyme sensitivity in these patients. ACE is reported increased in no more than 37% of patients with cardiac sarcoidosis while lysozyme in about 60% of patients [14]. Baba., et al. in 2012 demonstrated that high sensitive cardiac troponin T was a better biomarker than ACE and ly-sozyme being increased in 8/12 patients with cardiac sar-coidosis (87.5%) [15].
In Christchurch hospital, angiotensin-converting enzyme (ACE) and cardiac troponin concentrations were detected in 18 patients to help the diagnosis but unfortunately, they were increased only in 25% and 30% of patients with cardi-ac sarcoidosis, respectively. All these studies underlined the 
necessity of a specific biomarker with an adequate sensitivi-ty to help the diagnosis of cardiac sarcoidosis and to predict disease severity [14-21].At the University Hospital of Florence, we retrospectively analyzed serum biomarkers of sarcoidosis in 6 patients with cardiac involvement diagnosed in the last 36 months. Four patients were male, mean age was 44,2 ± 7,9 (M ± DS), they were no smoker only one was ex-smoker. Three of these young patients had an asymptomatic cardiac localization discovered after a total body PET demonstrating in all cases a pulmonary, lymph node and cardiac sarcoidosis and in a patient also salivary glands localizations. Diagnosis of car-
diac involvement was furtherly confirmed by cardiac nucle-ar magnetic resonance and mediastinal lymph node biopsy. The fourth patient presented an acute ventricular tachycar-dia induced under strain during a basket match. Cardiac nu-
clear magnetic resonance confirmed the presence of catting granulomas as well as PET that allowed also the discovery of hepatic and spleen involvements. Hepatic granulomas his-
tologically confirmed allowed to perform the diagnosis of 
cardiac sarcoidosis. The fifth patient was a female and she referred severe dyspnea and recurrent episodes of arrhyth-mias. The patient presented normal lung function parame-
ters with a mild reduction of DLCO percentage (65%). High resolution computed tomography of the chest revealed the presence of bilateral micro nodules, ground glass opacities and consolidation in the upper lung lobes. Supraventricu-lar tachycardia was registered through 24h Holter monitor and magnetic resonance imaging (MRI) revealed diffuse myocardial thickening and intra-myocardial focal zones with high signal intensity. The last patient with undiag-nosed sarcoidosis presented an acute onset of the disease with chest pain, breathing and severe ventricular tachycar-
dia requiring endocardial ablation and defibrillator. The 
diagnosis was performed by cardiac MRI and confirmed by broncho alveolar lavage (increased lymphocyte percentage greater than 40% were associated with CD4/CD8 ratio 4.8) and bronchial biopsy demonstrating sarcoidosis granulo-mas. PET, echo abdomen and high resolution computed to-
mography (HRCT) of the chest confirmed pulmonary sar-coidosis and minimal spleen involvement.In all six patients, serological analysis of ACE, C-reactive protein and chitotriosidase were performed at the onset (before starting steroid therapy). None of them presented increased ACE concentrations that resulted 41.11 ± 25.35 U/l (normal values < 65U/l), they have normal CRP levels (< 8mg/l), only serum chitotriosidase was highly increased in all cases with mean concentrations 169.54 ± 98.76 nmo-l/h/ml (normal values 45 nmol/h/ml). Interestingly the highest values of chitinase 1 (greater than 200) were ob-served in the last 3 patients who also presented the highest PET positivity and greater cardiac MRI involvement. Al-
though in a limited population, chitotriosidase for the first time was reported increased in patients affected by cardiac sarcoidosis; this chitinase needs to be further studied in larger population as it may help to distinguish sarcoidosis from systemic diseases associated with cardiac involve-ment [22,23]. In fact, several research studies suggest that very high enzyme levels (10 folds greater than controls as in our patients) are present only in sarcoidosis and not in 
other inflammatory systemic disorder including granulo-matosis [22-26].
Further studies in a larger population cohort are re-quired to evaluate human chitotriosidase levels in active 
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